article thumbnail

No Take-Backs: Moderna’s Attempt to Renege on its Vaccine Patent Pledge

Bill of Health

Like the Open COVID Pledge before it, Moderna’s pledge expressly states that it is valid only “ while the pandemic continues. government purchased millions of doses of Moderna’s mRNA vaccine, along with large quantities of vaccines manufactured by Pfizer. Pfizer made such a vaccine. From 2020 to 2022, the U.S.

article thumbnail

The Case for Procurement Transparency

Bill of Health

By Tara Davis and Nicola Soekoe In January 2021, the Director General of the World Health Organization (WHO) observed that the world was on the brink of a “catastrophic moral failure” if wealthier nations did not ensure the equitable distribution of COVID-19 vaccines. Impact of the judgment: what have records disclosed shown?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

COVID-19 Showcased Failed Global Cooperation

Bill of Health

By noting that non-state actors, such as the pharmaceutical industry, have a “duty to respect human rights in the context of a public health emergency,” the Principles acknowledge the outsized power of non-state actors in global health, and the ways in which they undermine solidarity in the face of a global health emergency.

COVID-19 303
article thumbnail

How the Life Sciences Industry Can Boost Diversity and Inclusion Efforts

HIT Consultant

The FDA is attempting to address this, having issued guidelines related to diversity in clinical trials in November 2020 – perhaps prompted by widespread media coverage of the fact that the black members of the society and other people of color were underrepresented in clinical trials for COVID-19 vaccines.

article thumbnail

Buried Under Dirt or Under Debt: Can Patients Survive the Struggle of Getting Care?

HIT Consultant

A recent report from the National Institutes of Health projected spending on specialty drugs to outpace growth in the pharmaceutical market, enough to exceed 50 percent of overall drug expenditures in 2021. These drugs bring the promise of positive clinical outcomes where they are most needed, so expanding access to them is imperative.

article thumbnail

2023’s Biggest Pharma Cybersecurity Threats to Watch

HIT Consultant

JP Perez-Etchegoyen, CTO of Onapsis Due to the recent growth of the pharmaceutical industry, the value of highly-sensitive data stored in pharmaceutical systems and the degree of the potential damage that cyberattacks on the industry can cause, it is safe to say that pharma could be one of the most targeted industries by cybercriminals in 2023.

article thumbnail

3 Lessons Learned from Pandemic-Era Clinical Development Regulatory Practices

HIT Consultant

The pandemic has given rise to new norms in drug development that will influence the future of the industry as we know it. The world has been in urgent need of COVID-19 vaccines, treatments, and diagnostic tools. Ronan Brown, SVP and Head of Integrated Global Compliance, IQVIA.